What is Bortezomib-lenalidomide-dexamethasone (VRd)?

Category: Prescription Drugs

false

See also: Bortezomib Lenalidomide

Bortezomib-lenalidomide-dexamethasone, also known as VRd, is a regimen that may be used for the treatment of multiple myeloma. It contains the anticancer agents bortezomib and lenalidomide along with dexamethasone, a corticosteroid.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 2
Moderate 14
Mild 15
None 0

Commonly reported side effects and conditions associated with Bortezomib-lenalidomide-dexamethasone (VRd)

Side effect Patients
Fatigue 10
Constipation 5
Diarrhea 4
Neuropathy in feet 3
Nerve pain (neuralgia) 2
Peripheral neuropathy 2

Show all 24 reported side effects

Dosages

Based on patients currently taking Bortezomib-lenalidomide-dexamethasone (VRd)

Dosage Patients
as needed 1
every other week 1
weekly 1

Why patients stopped taking Bortezomib-lenalidomide-dexamethasone (VRd)

Multiple reasons could be selected

Reason Patients
Course of treatment ended 17
Side effects too severe 7
Doctor's advice 6
Other 3
Did not seem to work 2
See all 28 patients who've stopped taking Bortezomib-lenalidomide-dexamethasone (VRd)

Duration

Currently taking Bortezomib-lenalidomide-dexamethasone (VRd)

Duration Patients
2 - 5 years 2
5 - 10 years 1
10 years or more 1

Stopped taking Bortezomib-lenalidomide-dexamethasone (VRd)

Duration Patients
Less than 1 month 1
1 - 6 months 20
6 months - 1 year 5
1 - 2 years 2
Adherence
Adherence Evaluations
Always 27
Usually 1
Sometimes 0
Never taken as prescribed 3
Burden
Burden Evaluations
Very hard to take 1
Somewhat hard to take 5
A little hard to take 10
Not at all hard to take 15
Cost per month
Cost per month Evaluations
$200+ 6
$100-199 1
$50-99 1
$25-49 4
< $25 7
Not specified 12

What people switch to and from

Patients started taking Bortezomib-lenalidomide-dexamethasone (VRd) after stopping:

Treatment Patients
Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD) 1
Bortezomib-dexamethasone (Vd) 1
Lenalidomide-dexamethasone (Rd) 1

Patients stopped taking Bortezomib-lenalidomide-dexamethasone (VRd) and switched to:

Treatment Patients
Lenalidomide (Revlimid) 5
Bortezomib (Velcade) 1
Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD) 1
Bortezomib-dexamethasone (Vd) 1
Carfilzomib (Kyprolis) 1

Show all 8 treatments patients report switching to

Last updated:
There are no evaluations for Bortezomib-lenalidomide-dexamethasone (VRd).